Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of EPX-100 in Healthy Adult Participants
NCT07879170Phase 1Recruiting
- Sponsor
- Epygenix Therapeutics
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clemizole in Dravet syndrome (4 arms), sponsored by Epygenix Therapeutics. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Aug 2026; status: recruiting.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT07879170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879170.